TY - JOUR
T1 - Correction to
T2 - Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (Leukemia, (2020), 34, 12, (3338-3347), 10.1038/s41375-020-0830-0)
AU - Dhakal, Binod
AU - Patel, Sagar
AU - Girnius, Saulius
AU - Bachegowda, Lohith
AU - Fraser, Raphael
AU - Davila, Omar
AU - Kanate, Abraham S.
AU - Assal, Amer
AU - Hanbali, Amr
AU - Bashey, Asad
AU - Pawarode, Attaphol
AU - Freytes, César O.
AU - Lee, Cindy
AU - Vesole, David
AU - Cornell, Robert Frank
AU - Hildebrandt, Gerhard C.
AU - Murthy, Hemant S.
AU - Lazarus, Hillard M.
AU - Cerny, Jan
AU - Yared, Jean A.
AU - Schriber, Jeffrey
AU - Berdeja, Jesus
AU - Stockerl-Goldstein, Keith
AU - Meehan, Kenneth
AU - Holmberg, Leona
AU - Solh, Melhem
AU - Diaz, Miguel Angel
AU - Kharfan-Dabaja, Mohamed A.
AU - Farhadfar, Nosha
AU - Bashir, Qaiser
AU - Munker, Reinhold
AU - Olsson, Richard F.
AU - Gale, Robert P.
AU - Bayer, Ruthlee Lu
AU - Seo, Sachiko
AU - Chhabra, Saurabh
AU - Hashmi, Shahrukh
AU - Badawy, Sherif M.
AU - Nishihori, Taiga
AU - Gonsalves, Wilson
AU - Nieto, Yago
AU - Efebera, Yvonne
AU - Kumar, Shaji
AU - Shah, Nina
AU - Qazilbash, Muzaffar
AU - Hari, Parameswaran
AU - D’Souza, Anita
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/6
Y1 - 2021/6
N2 - The acknowledgement of the original article was incomplete. Correct is should read: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741, and U01HL128568 from the NHLBI; HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1- 2705 and N00014-20-1-2832 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01C A218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI 069197, U01AI126612, UG1HL06924, and BARDA. Support is also provided by Be the Match Foundation, Boston Children’s Hospital, Dana Farber, St. Baldrick’s Foundation, Stanford University, the Medical College of Wisconsin the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals, Inc.; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. The original article has been corrected.
AB - The acknowledgement of the original article was incomplete. Correct is should read: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; U24CA233032 from the NCI; OT3HL147741, and U01HL128568 from the NHLBI; HHSH250201700006C, and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-20-1- 2705 and N00014-20-1-2832 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01C A218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI 069197, U01AI126612, UG1HL06924, and BARDA. Support is also provided by Be the Match Foundation, Boston Children’s Hospital, Dana Farber, St. Baldrick’s Foundation, Stanford University, the Medical College of Wisconsin the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals, Inc.; Adienne SA; Allovir, Inc.; Amgen, Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell, Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85103400893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103400893&partnerID=8YFLogxK
U2 - 10.1038/s41375-021-01233-1
DO - 10.1038/s41375-021-01233-1
M3 - Comment/debate
C2 - 33782538
AN - SCOPUS:85103400893
SN - 0887-6924
VL - 35
SP - 1828
JO - Leukemia
JF - Leukemia
IS - 6
ER -